Acitretin

證據等級: L5

預測適應症: 4 個

Acitretin: From Psoriasis to Acne (Disease)

One-Sentence Summary

Acitretin is a second-generation aromatic synthetic retinoid, globally established for the treatment of severe psoriasis and keratotic skin disorders, though it currently holds no marketing authorization in Taiwan. The TxGNN model predicts it may be effective for Acne (Disease), with no directly relevant clinical trials and 18 publications (predominantly reviews, observational data, and case reports on acitretin and retinoids in acne-related conditions) currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Psoriasis / Keratotic skin disorders (established global indication; no Taiwan registration)
Predicted New Indication	Acne (Disease)
TxGNN Prediction Score	99.94%
Evidence Level	L3
Saudi Arabia Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data from regulatory databases is not available in this evidence pack. Based on established pharmacological knowledge, acitretin is the active metabolite of etretinate and belongs to the second-generation aromatic retinoids. It exerts its effects by binding to nuclear retinoid receptors (RARα/β/γ), which triggers transcriptional changes that normalize follicular keratinization, suppress excessive sebaceous gland secretion, and inhibit inflammatory mediator release — including leukotriene LTC4 from eosinophils. These three mechanisms directly address the core pathophysiology of acne: sebaceous hyperactivity, follicular plugging, and chronic inflammation.

The strongest evidence for this repurposing direction lies in acne inversa (hidradenitis suppurativa, HS) — a severe, recurrent inflammatory follicular disease considered mechanistically related to nodulocystic acne. Acitretin is explicitly named in the European S1 clinical guideline for HS, and long-term observational data (up to 25 years) documents its efficacy in this population. Direct evidence for conventional acne vulgaris is limited to case reports where acitretin was used after isotretinoin showed only partial response.

It is important to note that isotretinoin (a first-generation retinoid) remains the established standard of care for severe conventional acne. Acitretin shares the nuclear receptor pathway but is better validated for HS and other keratotic disorders. Its potential role in acne therapy is therefore positioned as a second-line alternative in special clinical circumstances — particularly for acne inversa — and must be accompanied by rigorous teratogenicity management (Pregnancy Category X; mandatory contraception for ≥3 years post-cessation due to potential reconversion to the long-acting etretinate in the presence of alcohol).

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04663906	N/A	Unknown	300	Observational study examining whether nasal mucosal dryness from oral retinoids increases COVID-19 infection risk in acne patients. Primary subject is isotretinoin, not acitretin; provides indirect class-level safety context only and does not constitute direct evidence for acitretin in acne treatment.

Note: No clinical trials directly evaluating acitretin for the treatment of acne (disease) were identified in ClinicalTrials.gov or ICTRP searches.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
25640693	2015	Clinical Guideline (European S1)	J Eur Acad Dermatol Venereol	European S1 guideline for hidradenitis suppurativa/acne inversa; formally recommends acitretin as a systemic treatment option for this severe follicular acne-related condition
20874789	2011	Observational Study	Br J Dermatol	25-year long-term results of acitretin therapy for hidradenitis suppurativa; demonstrates sustained clinical benefit in a condition closely related to nodulocystic acne
9074840	1997	Review	Drugs	Comprehensive overview of retinoid use across 15 years; covers acitretin's role in severe acne and acne-related dermatoses, alongside psoriasis and keratotic genodermatoses
41692081	2026	Review	Clin Dermatol	Current overview of vitamin A and retinoids in dermatology; positions oral retinoids including acitretin within contemporary acne treatment frameworks
29234829	2018	Review	Hautarzt	Drug therapy of acne inversa; discusses acitretin within the systemic treatment algorithm alongside antibiotics and biologics
26617362	2016	Review	Dermatol Clin	Medical treatments for hidradenitis suppurativa; acknowledges low evidence levels but documents promising results for acitretin pending RCT validation
1617858	1992	PK/Efficacy Review	Clin Pharmacokinet	Pharmacokinetics and efficacy of retinoids including acitretin; confirms second-generation retinoid profile and primary indication in keratotic disorders with implications for acne
8573927	1995	Mechanistic Study	Dermatology	Examines retinoid inhibition of sebaceous gland activity as the mechanistic basis for anti-acne efficacy; explores whether acitretin can replicate isotretinoin's effect on sebaceous suppression
2112772	1990	Mechanistic Study	Prostaglandins	Acitretin inhibits eosinophil LTC4 release; supports the anti-inflammatory mechanism underlying its efficacy in acne and psoriasis
12080949	2002	Case Report	Cutis	Direct case report: patient with severe nodulocystic facial acne and hidradenitis suppurativa treated with acitretin after two courses of isotretinoin showed only partial response; acitretin resolved persistent draining cysts

Saudi Arabia Market Information

Acitretin currently holds no marketing authorizations in Taiwan. No license records, approved dosage forms, or registered indications are on file.

Safety Considerations

Please refer to the package insert for complete safety information, as formal warning and contraindication data was not available in this evidence pack.

Critical class-level risk (pharmacological basis): Acitretin is an absolute teratogen (Pregnancy Category X). Unlike isotretinoin (contraception required for 1 month post-cessation), acitretin can be re-esterified to the long-acting etretinate in the presence of alcohol, extending the teratogenic risk period to ≥3 years after treatment cessation. This is the defining safety constraint for any acitretin repurposing program and must be reflected in all prescribing guardrails and patient selection criteria.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Acitretin's nuclear retinoid receptor mechanism directly targets the pathophysiological drivers of acne, and its efficacy in the closely related acne inversa (HS) is supported by a European S1 clinical guideline and long-term observational data. However, direct RCT evidence for conventional acne vulgaris is absent, and the teratogenicity profile demands strict prescribing controls.

To proceed, the following is needed:

Indication scoping: Clarify whether the target is acne inversa/HS (where L3 evidence and guideline support already exists) or conventional acne vulgaris (where only indirect and mechanistic data is available)
MOA documentation: Retrieve complete pharmacological profile from DrugBank (DB00459) and package inserts
Safety data retrieval: Download and parse package insert PDF from TFDA for formal warnings, contraindications, and DDI data (currently Blocking data gap)
Teratogenicity management protocol: Develop a pregnancy prevention program (PPP) analogous to iPLEDGE (isotretinoin) or Pregnancy Prevention Programme (acitretin, EU), including alcohol abstinence counseling and extended contraception requirements
Market registration assessment: Evaluate feasibility of Taiwan NDA submission given zero current authorizations and the need for a full teratogenicity risk management strategy
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.